Lack of drug-drug interaction between cerivastatin and nifedipine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 8, 1998, Pages 409-413

  Sachse, R ^a,b   Brendel, E ^a   Muck W ^a   Rohde, G ^a   Ochmann, K ^a   Horstmann, R ^a   Kuhlmann, J ^a  

^a BAYER AG   (Germany)

^b MEDA Manufacturing GmbH   (Germany)

Author keywords

Cerivastatin; Cytochrome P450 3A4; Dihydropyridine calcium antagonist; HMG CoA reductase inhibitor; Nifedipine; Pharmacokinetic interaction

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMETHYLATION; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NIFEDIPINE; PYRIDINES;

EID: 0031854722     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Angerbauer R, Bischoff H, Steinke W, Ritter W 1994 BAY W 6228. Drugs Future 19: 537-541
2. Bailey DG, Edgar B, Spence JD, Munoz C, Arnold JMO 1990 Felodipine and nifedipine interactions with grapefruit juice. Clin Pharmacol Ther 47: 180
3. Boberg M, Angerbauer R, Fey P, Kanhai W, Karl W, Kern A, Ploschke J, Radtke M 1997 Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331
4. Brodgen RN, McTavish D 1995 Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 50: 495-512
5. Czyborra P, Kremens B, Brendel E, Bald M, Michel MC 1998 Fluconazole enhances blood pressure-lowering effects of nifedipine in a patient with malignant phaeochromocytoma. Naunyn Schmiedebergs Arch Pharmacol 357 (Suppl): R165
6. Guengerich FP 1987 Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262: 8459-8462
7. Guengerich FP, Böcker RH 1988 Cytochrome P-450-catalyzed dehydrogenationof 1,4 dihydropyridines. J Biol Chem 263: 8168-8175
8. Hsu I, Spinler SA, Johnson NE 1995 Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolaemia. Ann Pharmacother 29: 743-759
9. Ikeda T, Ishigami M, Yamazoe Y 1997 Inhibition of hepatic cytochrome P450 isoform, CYP3A, by 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Atherosclerosis 134: 135
10. Khan A, Langley SJ, Mullins FG, Dixon JS, Toon S 1991 The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol 32: 519-522
11. Kjekshus J, Pedersen TR 1995 Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76: 64C-68C
12. Krol GJ, Beck GW, Ritter W, Lettieri JT 1993 LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
13. Lettieri J, Krol G, Mazzu A, Fiebach MZ, Heller AH 1997 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis 130 (Suppl): S29
14. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J 1997a Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35: 255-260
15. Mück W, Ochmann K, Mazzu A, Lettieri J 1997b Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor. Atherosclerosis 134: 130
16. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35: 261-264
17. Mück W, Ritter W, Frey R, Wetzelsberger N, Lücker PW, Kuhlmann J 1997d Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35: 250-254
18. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J 1998a No drug-drug interaction between cerivastatin and omeprazole. Naunyn Schmiedebergs Arch Pharmacol 357 (Suppl): R175
19. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J 1998b Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53: 469-473
20. Mück W, Kawano K, Ahr G 1998c Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol in press
21. Radtke M, Boberg M, Kanhai W, Kern A, Leega A, Nowak K 1997 Cerivastatin: Identification of human cytochrome P-450 isozymes involved in the biotransformation of the drug and two active metabolites. Abstract at the North American ISSX Meeting, Hilton Head, SC/USA, October 26-30
22. Raemsch KD, Graefe KH, Scherling D, Sommer J, Ziegler R 1986 Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol 6 (Suppl 1): 73-80
23. Sachse R, Brendel E, Mück W, Rohde G, Ochmann K, Horstmann R 1998 No drug-drug interaction between cerivastatin and nifedipine. Naunyn Schmiedebergs Arch Pharmacol 357 (Suppl): R174
24. Schall R, Mueller FO, Hundt HK, Ritter W, Duursema L, Groenewoud G, Middle MV 1995 No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol 35: 306-313
25. Schulz J, Schmidt J, Ruck W 1996 The value of nifedipine in the treatment of hypertension, coronary heart disease, and myocardial infarction (post-infarction therapy). Curr Med Res Opin 13: 397-408
26. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 333: 1301-1307
27. Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR 1997 Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 2: 7-16
28. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, Göller G, Schwarz T, Siefert HM 1996 Cerivastatin, a new inhibitor of HMG-CoA reductase. Pharmacokinetcs in rats and dogs. Jpn Pharmacol Ther 24 (Suppl 9): 1217-1237
29. Wrighton SA, Ring BJ 1994 Inhibition of human CYP 3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11: 921-924